Get the Stockscreener App
1.15
3.60%
0.04
After Hours:
1.14
-0.01
-0.87%
Lexicon Pharmaceuticals Inc stock is traded at $1.15, with a volume of 1.68M.
It is up +3.60% in the last 24 hours and up +8.49% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.11
Open:
$1.1
24h Volume:
1.68M
Relative Volume:
0.51
Market Cap:
$417.91M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.4375
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
+5.50%
1M Performance:
+8.49%
6M Performance:
+201.92%
1Y Performance:
-31.14%
1-Day Range:
$1.10
$1.15
1-Week Range:
$1.05
$1.15
52-Week Range:
$0.2836
$2.175
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.15 | 392.47M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings - The Manila Times
Lexicon Pharmaceuticals Presents Promising Data on Pilavapadin for Diabetic Peripheral Neuropathic Pain at Upcoming Medical Meetings - Quiver Quantitative
Lexicon Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming ... - nrtoday.com
Novel Non-Opioid Pain Drug Data: Lexicon's Pilavapadin Shows Promise for Diabetic Neuropathy Treatment - Stock Titan
Lexicon Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals at H.C. Wainwright: Strategic Program Updates By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals at H.C. Wainwright: Strategic Program Updates - Investing.com
Lexicon Submits Additional Benefit-Risk Data to FDA for Sotagliflozin for Type 1 Diabetes - HCPLive
Lexicon submits new data to FDA for potential diabetes drug approval - Investing.com
Lexicon submits new data to FDA supporting Zynquista's use in type 1 diabetes - MarketScreener
FDA Update: Lexicon's Diabetes Drug Zynquista Gets New Clinical Data Support from 3 Major Centers - Stock Titan
Real time alert setup for Lexicon Pharmaceuticals Inc. performanceTrade Entry Report & Smart Money Movement Tracker - Newser
Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives Buy Rating from HC Wainwright - MarketBeat
Can trapped investors hope for a rebound in Lexicon Pharmaceuticals Inc.Profit Target & Verified Stock Trade Ideas - Newser
Price action breakdown for Lexicon Pharmaceuticals Inc.2025 Support & Resistance & Low Risk High Reward Trade Ideas - Newser
What is Lexicon Pharmaceuticals Inc.’s valuation compared to sectorDividend Hike & Low Drawdown Investment Ideas - خودرو بانک
Using Python tools to backtest Lexicon Pharmaceuticals Inc. strategies2025 Big Picture & Safe Capital Growth Tips - Newser
What is Lexicon Pharmaceuticals Inc.’s book value per shareLayoff News & High Return Stock Watch Alerts - خودرو بانک
What’s the MACD signal for Lexicon Pharmaceuticals Inc.Weekly Market Outlook & Short-Term High Return Ideas - خودرو بانک
Nantahala Capital Management LLC Decreases Stock Position in Lexicon Pharmaceuticals, Inc. $LXRX - MarketBeat
Can Lexicon Pharmaceuticals Inc. ride the EV waveOil Prices & Safe Capital Growth Stock Tips - خودرو بانک
How to build a dashboard for Lexicon Pharmaceuticals Inc. stockJuly 2025 Sector Moves & Short-Term High Return Ideas - Newser
Is Lexicon Pharmaceuticals Inc. meeting your algorithmic filter criteriaJuly 2025 Summary & Trade Opportunity Analysis Reports - Newser
Heatmap analysis for Lexicon Pharmaceuticals Inc. and competitors2025 Price Action Summary & High Return Trade Guides - Newser
How to escape a deep drawdown in Lexicon Pharmaceuticals Inc.2025 Trading Volume Trends & Safe Entry Trade Reports - Newser
Using portfolio simulators with Lexicon Pharmaceuticals Inc. includedQuarterly Performance Summary & Risk Adjusted Swing Trade Ideas - Newser
Will Lexicon Pharmaceuticals Inc. continue its uptrendGap Up & Weekly Setup with High ROI Potential - Newser
What is Lexicon Pharmaceuticals Inc.’s TAM (Total Addressable Market)2025 Price Targets & Verified Swing Trading Watchlists - خودرو بانک
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 - Yahoo Finance
Top chart patterns to watch in Lexicon Pharmaceuticals Inc.Portfolio Gains Summary & Free Expert Verified Stock Movement Alerts - Newser
Combining price and volume data for Lexicon Pharmaceuticals Inc.Exit Point & Risk Controlled Swing Alerts - Newser
Novel Pain Treatment Breakthrough: Lexicon's Pilavapadin Shows Promise for MS and Chemo Patients - Stock Titan
Analyzing net buyer seller activity in Lexicon Pharmaceuticals Inc.Quarterly Trade Report & Daily Market Momentum Tracking - Newser
Lexicon Pharmaceuticals Inc. stock momentum explainedCPI Data & Daily Profit Maximizing Tips - Newser
Lexicon Pharmaceuticals' Strategic R&D Pivots and Licensing Catalysts in 2025 - AInvest
Lexicon Pharmaceuticals' Strategic Positioning in the Biopharma Sector - AInvest
Can Lexicon Pharmaceuticals Inc. generate free cash flow2025 Valuation Update & Weekly High Conviction Ideas - خودرو بانک
Siren L.L.C. Sells 35,402,689 Shares of Lexicon Pharmaceuticals, Inc. $LXRX - MarketBeat
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 - The Manila Times
Lexicon Pharmaceuticals to Present Patient Insights on Diabetic Peripheral Neuropathic Pain at PAINWeek 2025 - Quiver Quantitative
30% of Diabetics Suffer Neuropathic Pain: Lexicon Study Reveals Impact on Daily Life at PAINWeek - Stock Titan
H.C. Wainwright reiterates Buy rating on Lexicon Pharmaceuticals stock at $4 By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Lexicon Pharmaceuticals stock at $4 - Investing.com
How to use a screener to detect Lexicon Pharmaceuticals Inc. breakouts2025 Performance Recap & High Accuracy Trade Alerts - Newser
Pattern recognition hints at Lexicon Pharmaceuticals Inc. upsideMarket Sentiment Report & Real-Time Chart Pattern Alerts - Newser
Update Recap: Can Lexicon Pharmaceuticals Inc. reach all time highs this year2025 Valuation Update & Real-Time Market Trend Scan - خودرو بانک
Buybacks Report: What’s the MACD signal for Lexicon Pharmaceuticals Inc.Market Volume Summary & Technical Entry and Exit Alerts - خودرو بانک
Lexicon Pharmaceuticals: HC Wainwright raises Buy rating, PT to $4. - AInvest
28% Heart Failure Risk Reduction: Lexicon's Sotagliflozin Proves Equally Effective in Elderly Patients Over 75 - Stock Titan
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):